IDH1 and central nervous system cancer: Indeed, although inhibition of IDH1 mutant with a selective IDH1mt inhibitor (AGI-5198) impaired glioma tumor growth in vitro and in vivo by blocking the production of 2HG [146], this IDH1mt inhibitor was reported to radio-protect IDH1 mutant cancer cells by decreasing radiation-induced ROS levels, DNA double-strand breaks and cell death, indicating that IDH1mt inhibition limits radiation efficacy [154].